Efficacy and safety of low-dose rituximab as induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: a Chinese case series

Efficacy and safety of low-dose rituximab as induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: a Chinese case series

Abstract Background Rituximab (RTX) is a standard therapy for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, the most frequently used dose may lead to severe adverse effects (SAEs). We explored the efficacy and safety of low-dose RTX in Chinese patients with AAV. Me...

Full description

Bibliographic Details
Main Authors: Lin Liu, Haitao Lu, Guming Zou, Haifeng Wang, Jing Li, Yue Yang, Jian Zhang, Xueling Wang, Wenge Li, Li Zhuo
Format: Article
Language:English
Published: BMC 2023-02-01
Series:BMC Nephrology
Subjects:
Antineutrophil cytoplasmic antibody-associated vasculitis
Rituximab
Low-dose
Renal injury
Online Access:https://doi.org/10.1186/s12882-023-03075-8

Internet

https://doi.org/10.1186/s12882-023-03075-8

Similar Items